Evidence map›Paper›PMID 22911846›Full record

ArticlePloS one2012

Characterizing tumor response to chemotherapy at various length scales using temporal diffusion spectroscopy.

Junzhong Xu, Ke Li, R Adam Smith, John C Waterton, Ping Zhao, Heidi Chen, Mark D Does, H Charles Manning, John C Gore

Abstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Engineering clinical translation of OGSE diffusion MRI.Magnetic resonance in medicine · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Junzhong XuInstitute of Imaging Science, Vanderbilt University, Nashville, Tennessee, United States of America. junzhong.xu@vanderbilt.edu
Ke Li
R Adam Smith
John C Waterton
Ping Zhao
Heidi Chen
Mark D Does
H Charles Manning
John C Gore

Funding

Vanderbilt In Vivo Cellular and Molecular Imaging CenterP50CA128323 · NCI · VANDERBILT UNIVERSITY · PI SHYR, YU · 2008 to 2012
$6.8M
MRI Diffusion in Tumors Using Oscillating GradientsR01CA109106 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI XU, JUNZHONG · 2006 to 2022
$4.0M
South-Eastern Center for Imaging Animal Models of CancerU24CA126588 · NCI · VANDERBILT UNIVERSITY · PI GORE, JOHN C · 2007 to 2011
$2.1M
Biological Basis of Imaging Biomarkers in Colorectal CancerR01CA140628 · NCI · VANDERBILT UNIVERSITY · PI MANNING, HENRY CHARLES · 2009 to 2013
$1.5M
NCI NIH HHS P50 CA128323NCI NIH HHS P50CA128323NCI NIH HHS R01 CA109106NCI NIH HHS R01CA109106NCI NIH HHS R01 CA140628NCI NIH HHS R01CA140628NCI NIH HHS U24 CA126588NCI NIH HHS U24CA126588
6 · The paper itself

Abstract

Measurements of apparent diffusion coefficient (ADC) using magnetic resonance imaging (MRI) have been suggested as potential imaging biomarkers for monitoring tumor response to treatment. However, conventional pulsed-gradient spin echo (PGSE) methods incorporate relatively long diffusion times, and are usually sensitive to changes in cell density and necrosis. Diffusion temporal spectroscopy using the oscillating gradient spin echo (OGSE) sequence is capable of probing short length scales, and may detect significant intracellular microstructural changes independent of gross cell density changes following anti-cancer treatment. To test this hypothesis, SW620 xenografts were treated by barasertib (AZD1152), a selective inhibitor of Aurora B kinase which causes SW620 cancer cells to develop polyploidy and increase in size following treatment, ultimately leading to cell death through apoptosis. Following treatment, the ADC values obtained by both the PGSE and low frequency OGSE methods increased. However, the ADC values at high gradient frequency (i.e. short diffusion times) were significantly lower in treated tumors, consistent with increased intracellular restrictions/hindrances. This suggests that ADC values at long diffusion times are dominated by tumor microstructure at long length scales, and may not convey unambiguous information of subcellular space. While the diffusion temporal spectroscopy provides more comprehensive means to probe tumor microstructure at various length scales. This work is the first study to probe intracellular microstructural variations due to polyploidy following treatment using diffusion MRI in vivo. It is also the first observation of post-treatment ADC changes occurring in opposite directions at short and long diffusion times. The current study suggests that temporal diffusion spectroscopy potentially provides pharmacodynamic biomarkers of tumor early response which distinguish microstructural variations following treatment at both the subcellular and supracellular length scales.

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorDiffusion Magnetic Resonance ImagingFemaleHumansMiceMice, NudeNeoplasmsPhantoms, ImagingSpectrum AnalysisSpin LabelsTime FactorsTreatment OutcomeXenograft Model Antitumor AssaysAntineoplastic AgentsSpin Labels

Identifiers

PMID22911846
PMCPMC3404000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.